Two of the eight individuals were under 40 years old, and to directly compare these relatives with appropriate controls we have screened a further 365 normal individuals aged 16-40 years. MBL-CLL was detectable in only 0.3% (1/365) of the otherwise normal young adults. The age distribution of MBL-CLL in normal individuals therefore mimics that of clinical CLL; in contrast the proportion of affected individuals in familial CLL is high at all ages. The overall relative risk for detection of MBL-CLL in families is fourfold in comparison to the general population but for young adults the relative risk rises to 17-fold ( Table 1 ). The detection of MBL-CLL is independent of ascertainment bias and provides strong confirmatory evidence of inherited genetic susceptibility to CLL in some families. The fact that familial CLL shares a similar range and frequency of the major prognostic factors 8 indicates that there is a pre-disposition to all types of CLL. The data suggests that, at least in a proportion of families, there is an inherited abnormality that increases susceptibility to development of CLL at a much earlier age than the general population, thus increasing the life-long risk of developing a clinically apparent CLL clone within the family as a whole.
Immunotherapy of B-cell malignancies with genetically engineered human CD8 þ natural killer T cells Adoptive T-cell immunotherapy is an attractive modality for the treatment of human hematologic malignancies. Genetic engineering of T lymphocytes with chimeric T-cell receptors (cTCR) has been shown to be a potent strategy for targeted immunotherapy. 1 A variety of cTCR have been constructed, some of which consist of a single-chain antibody variable fragment (scFv) with tumor antigen specificity linked to the constant region of the CD3z-chain of the TCR. 2 cTCR expressing T lymphocytes can bypass MHC-restricted target recognition and have shown significant tumor responses in models. However, clinical efficacy in humans is, as yet limited. The reasons for this are not well understood, but incomplete activation via the signaling domain of the CD3z-chain is thought to be one major limitation for successful clinical application.
3 Table 1 Relative risk of detection of CLL-phenotype monoclonal B-cell lymphocytosis in the general population and in normal relatives from CLL families In this study, cellular cytotoxicity of ex vivo expanded human CD8 þ natural killer T (NKT) cells was redirected using CD20 antigen-specific cTCR as a novel approach to cellular immunotherapy for B-cell malignancies. CD8
þ NKT cells are found in small percentages in human peripheral blood or bone marrow and readily expanded in culture by timed addition of interferon-g (IFN-g), followed by a-CD3 antibody and interleukin-2 (IL-2). 4 
Ex vivo expanded CD8
þ NKT cells coexpress surface markers of both T cells (CD3, CD8, abTCR) and natural killer (NK) cells (CD56). These immunological effector cells, which also have been referred to as cytokine-induced killer (CIK) cells, show potent MHC-unrestricted cytotoxicity against various tumor cell lines and fresh tumor isolates. 5 The precise mechanism of tumor targeting by CD8
þ NKT cells has not been fully elucidated. Previous investigations demonstrated that target cell recognition involves the interaction of adhesion molecules, for example LFA-1/ICAM-1, and the stimulation of NKG2D, a member of the c-type lectin-activating receptor family. 6 Following 3 weeks in culture, CD8
þ NKT cells upregulate a number of effector molecules with perforin being the most relevant for mediating cellular cytotoxicity.
Human CD8 þ NKT cells were ex vivo expanded as described earlier with minor modifications. 7 On day 1, IFN-g (1000 units/ ml) was added to freshly obtained peripheral blood mononuclear cells (PBMCs). On day 2, cells were preactivated with immobilized a-CD3, and a-CD28 mAbs. On day 3, cells were transduced using a SFG retroviral vector, subcloned with the chimeric receptor gene CD20z, with specificity for the B-cell surface molecule CD20. The CD20z chimeric receptor gene incorporates the variable domains of a monoclonal antibody (clone HB13b), 8 assembled as a single chain Fv (scFv) molecule cloned in frame with a sequence encoding the human IgG1 hinge domain, and the transmembrane as well as the cytoplasmatic domains of the human T-cell receptor CD3z-chain (provided by H Zola, University of Adelaide, Australia). The scFv/hinge/z cDNA was subcloned into BamHI and NcoI sites of the retroviral vector SFG (provided by RC Mulligan, Cambridge, MA, USA).
For transduction experiments, viral supernatant was generated by transient transfection of the human packaging cell line Phoenix-ampho (embryonic kidney cells) using GeneJuicet lipofection reagent. On day 1, transfected cells were resuspended in DMEM containing 20% FBS, and L-glutamine 2 mM. On day 2, retroviral supernatants were harvested and the human packaging cell line FLYRD18 (fibrosarcoma cells) was infected for 12-24 h in the presence of 4 mg/ml protamine sulfate. On days 3-18, viral supernatants were replaced on a daily basis, adding fresh media. Before transduction of PBMCs, viral supernatants were filtered through a 0.45 mm filter. At 48-72 h after infection, transduced PBMCs were washed to remove virus and expanded over 3 weeks in culture by adding twice weekly fresh AIM V medium, IL-2, and IL-15 (300 units/ml, and 50 ng/ ml, respectively). After 3 weeks, transduced bulk cultures expanded 179-to 299-fold (nontransduced controls: 168-to 399-fold). On day 21, CD8
þ NKT cells were isolated by CD56 antigen-directed immunomagnetic cell separation (purity 495%). Contaminants of the enriched CD8 þ NKT cell population consisted primarily of T cells coexpressing the surface markers CD3, CD8, a/b TCR (o4%), and a very small subset of NK cells (o0.5%) coexpressing CD16, CD56. Flow cytometric analyses were performed using a monoclonal antibody directed against the extracellular domain F(ab 0 ) 2 Figure 1c ). Cold target inhibition assays were performed to further dissect CD20 antigen-specific from nonspecific tumor targeting. Transduced CD8
þ NKT cells were coincubated with various nonlabeled (cold) targets before a 4-h 51 Cr-release assay with labeled (hot) CD20
þ Daudi targets (Figure 1d ). When using the NKT cell sensitive cell line HSB-2 (CD20 À ) as cold targets, nonspecific activity was inhibited and CD20 antigen-restricted cytotoxicity was measured at 36% (cold:hot 80:1). When using the NKT less sensitive cell line Raji (CD20 þ ) as cold targets, CD20 antigen-mediated activity was inhibited, and nonspecific cytotoxicity was measured at 20% (cold:hot 80:1). In control experiments using the NKT sensitive Daudi cell line (CD20 þ ) as cold targets the combined blockage of nonspecific and chimeric receptor-mediated target cell recognition was measured at 13% (cold:hot 80:1). When using the NKT less sensitive A-204 cell line (CD20 À ) as cold targets, the combined nonspecific and chimeric receptor-mediated cytotoxicity was measured at 59% (cold:hot 80:1). These results provide evidence that CD8 þ NKT cells use multiple pathways of target recognition. Additionally, chimeric receptor-mediated tumor targeting was found to increase cytotoxic activity of CD8 þ NKT cells against CD20 Cr-release assays using CD20 þ Raji targets, chimeric receptor mediated cytotoxicity of transduced CD8 þ NKT cells was found to be significantly higher as compared to transduced CD8 þ T cells (mean: 65% cTCR þ CD8 þ NKT cells vs 21% cTCR þ CD8 þ T cells; E:T 40:1, P ¼ 0.021; Figure 1e ). In addition, nonspecific tumor targeting of ex vivo expanded CD8 þ NKT cells against Raji tumor cells was found to be more potent than that of ex vivo expanded CD8 þ T cells (mean: 22% CD8 þ NKT cells vs 9% CD8 þ T cells; E:T 40:1, P ¼ 0.021; Figure 1e ). Of note, both transduced and nontransduced CD8 þ NKT cells showed nonspecific cytotoxicity against A-204 tumor cells (CD20 À ), whereas CD8 þ T cells had no relevant cytotoxic activity against these targets (data not shown).
The role of adhesion molecules on chimeric receptormediated cytotoxicity of transduced CD8 þ NKT cells was examined by receptor blocking with monclonal antibodies before 4-h 51 Cr-release assays. We observed that blocking LFA-1 and ICAM-1 did only moderately decrease cytotoxicity of cTCR þ CD8 þ NKT cells against Daudi cells (mean: 64.9% without mAbs, 58.6% with a-LFA-1 mAb, 50.6% with a-ICAM-1 mAb; E:T ratio 40:1). These results suggest that cytotoxicity of CD8 þ NKT cells redirected by the chimeric receptor is to a great extent independent from adhesion molecule interaction. However, we found that crossblocking the CD20 molecule by adding an a-CD20 IgG1 mAb (rituximab) partially inhibited chimeric receptor mediated cytotoxicity of CD8 þ NKT cells, which demonstrates evidence that the chimeric receptor is involved in target cell recognition (mean: 64.9% without, 43.8% with a-CD20 mAb; E:T ratio 40:1).
In addition, chimeric receptor signaling of transduced effector cells was evaluated by measuring IFN-g secretion in response to target cell interaction using an enzyme-linked immunosorbent assay. High levels of IFN-g were detected only when cTCR þ
CD8
þ NKT cells were coincubated with CD20 þ targets (Daudi, mean: 27.8 ng/ml cTCR þ CD8 þ NKT cells vs 0.8 ng/ml controls, P ¼ 0.043; Raji, mean: 13.3 ng/ml cTCR þ CD8 þ NKT cells vs 1.1 ng/ml controls, P ¼ 0.043; Figure 1f ). In contrast, coincubation with CD20 À targets resulted in significantly lower IFN-g secretion (A-204, mean: 0.025 ng/ml cTCR þ
þ NKT cells vs 0.014 ng/ml controls, P ¼ 0.191; HSB-2, mean: 0.091 ng/ml cTCR þ CD8 þ NKT cells vs 0.11 ng/ml controls; P ¼ 0.773; Figure 1f) .
In summary, we report on a novel protocol for the ex vivo generation of CD8 þ NKT cells expressing chimeric T-cell receptor genes consisting of an extracellular scFv mAb with high Cr release or as the means7s.e.m. of the cytokine secretion (ng/ml). P-values less than or equal to 0.05 were considered significant.
Letters to the Editor specificity for the CD20 molecule for potential use in adoptive immunotherapy of B-cell malignancies. We show that cTCR þ
þ NKT cells can be expanded in large quantities and are highly effective in lysing CD20 molecule expressing Daudi and Raji tumor cell lines, as well as freshly isolated malignant B lymphocytes from B-CLL patients. In competitive targeting studies, we were able to dissect the major pathways of tumor cell recognition and found that endowing CD8 þ NKT cells with CD20z chimeric receptors resulted in a significant increase of cytotoxic activity against CD20
þ Daudi targets as compared to nontransduced effectors.
We also demonstrate that chimeric receptor mediated cytotoxicity is dependent on the expression level of the target antigen. Tumor targets expressing high levels of CD20 molecule (Daudi) were lysed more efficiently than low level expressing targets (Raji). Of importance, cytotoxicity of ex vivo expanded cTCR þ CD8 þ NKT cells was more potent as compared to ex vivo expanded cTCR þ CD8 þ T cells. We believe these differences in cytotoxic activity to be a result of cultured CD8 þ T cells being sensitized for activation induced cell death (AICD) following repetitive stimulation with IL-2. In addition, functional cTCR signaling was documented by detection of high levels of the Th-1 cytokine IFN-g secreted by cTCR þ CD8 þ NKT cells upon CD20 antigen target recognition. Of interest, blocking the adhesion molecules LFA-1/ICAM-1 had no major influence on chimeric T-cell receptor mediated cytotoxicity of CD8 þ NKT cells. Our results suggest that cellular immunotherapy using human ex vivo expanded CD8 þ NKT cells expressing CD20 antigenspecific cTCR could add to standard treatment regimens for CD20 þ B-cell malignancies, for example to overcome recurrent or refractory disease, with the advantage of minor additional toxicity. However, further studies are needed to determine the optimal use of genetically engineered cTCR þ CD8 þ NKT cells. Finally, the proposed immunotherapeutic strategy may also be applicable to other neoplastic diseases by modification of the candidate gene. Multiple myeloma (MM) is a hematological malignancy characterized by accumulation in the bone marrow of plasma cells that secrete a monoclonal immunoglobulin (Ig). The implication of natural killer cells (NK) in antitumor immunity against MM is suggested by plasmocyte susceptibility to NK lysis.
1 NK efficiently kill early-stage MM cells by a natural cytotoxicity receptor (NCR)-and NKG2D-dependent pathway. 2 In contrast, late-stage MM cells are protected from NK lysis by a high expression of HLA class I molecules. 2 In addition to this immune evasion mechanism involving the target cell, 2 we tested the hypothesis of an additional mechanism involving the effector cell, that is, NK, as previously described in leukemic patients. 3 We analyzed peripheral NK from six MM patients at diagnosis. The activating receptor expression was checked on CD19 À CD3 À CD56 þ cells by flow cytometry using mAbs against NKp30, NKp44, NKp46, NKG2D, CD16 and 2B4/CD244 (for patient descriptions, see Supplementary Information).
In MM patients, the percentage of NKp30-expressing NK (69%718) and the mean fluorescence intensity (MFI ¼ 42731) did not statistically differ (P ¼ 0.28, Mann-Whitney non-parametric test; Figure 1 ) from 23 healthy donors (86%711 positive cells, MFI ¼ 56737). In MM patients, the percentage of NKp46-expressing NK (80%715) and the MFI (62735) did not
